Gastroenterology Unit, Valduce Hospital, Como, Italy.
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Gastroenterology and Hepatology, Milan, Italy.
Endoscopy. 2022 Dec;54(12):1171-1179. doi: 10.1055/a-1849-6878. Epub 2022 May 11.
Computer-aided detection (CADe) increases adenoma detection in primary screening colonoscopy. The potential benefit of CADe in a fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening program is unknown. This study assessed whether use of CADe increases the adenoma detection rate (ADR) in a FIT-based CRC screening program.
In a multicenter, randomized trial, FIT-positive individuals aged 50-74 years undergoing colonoscopy, were randomized (1:1) to receive high definition white-light (HDWL) colonoscopy, with or without a real-time deep-learning CADe by endoscopists with baseline ADR > 25 %. The primary outcome was ADR. Secondary outcomes were mean number of adenomas per colonoscopy (APC) and advanced adenoma detection rate (advanced-ADR). Subgroup analysis according to baseline endoscopists' ADR (≤ 40 %, 41 %-45 %, ≥ 46 %) was also performed.
800 individuals (median age 61.0 years [interquartile range 55-67]; 409 men) were included: 405 underwent CADe-assisted colonoscopy and 395 underwent HDWL colonoscopy alone. ADR and APC were significantly higher in the CADe group than in the HDWL arm: ADR 53.6 % (95 %CI 48.6 %-58.5 %) vs. 45.3 % (95 %CI 40.3 %-50.45 %; RR 1.18; 95 %CI 1.03-1.36); APC 1.13 (SD 1.54) vs. 0.90 (SD 1.32; = 0.03). No significant difference in advanced-ADR was found (18.5 % [95 %CI 14.8 %-22.6 %] vs. 15.9 % [95 %CI 12.5 %-19.9 %], respectively). An increase in ADR was observed in all endoscopist groups regardless of baseline ADR.
Incorporating CADe significantly increased ADR and APC in the framework of a FIT-based CRC screening program. The impact of CADe appeared to be consistent regardless of endoscopist baseline ADR.
计算机辅助检测(CADe)可提高结肠镜检查初级筛查中的腺瘤检出率。CADe 在粪便免疫化学检测(FIT)为基础的结直肠癌(CRC)筛查项目中的潜在获益尚不清楚。本研究评估了在 FIT 为基础的 CRC 筛查项目中使用 CADe 是否会提高腺瘤检出率(ADR)。
在一项多中心、随机试验中,接受结肠镜检查的 FIT 阳性、年龄在 50-74 岁之间的个体,按 1:1 比例随机分为接受高清白光(HDWL)结肠镜检查的组,或接受有基线 ADR>25%的内镜医师实时使用深度学习 CADe 的组。主要结局是 ADR。次要结局是每例结肠镜检查的平均腺瘤数(APC)和高级别腺瘤检出率(advanced-ADR)。还根据基线内镜医师 ADR(≤40%、41%-45%、≥46%)进行了亚组分析。
共纳入 800 名个体(中位年龄 61.0 岁[四分位间距 55-67];409 名男性):405 名接受 CADe 辅助结肠镜检查,395 名仅接受 HDWL 结肠镜检查。CADe 组的 ADR 和 APC 显著高于 HDWL 组:ADR 为 53.6%(95%CI 48.6%-58.5%) vs. 45.3%(95%CI 40.3%-50.45%;RR 1.18;95%CI 1.03-1.36);APC 为 1.13(SD 1.54) vs. 0.90(SD 1.32;P=0.03)。两组 advanced-ADR 无显著差异(分别为 18.5%[95%CI 14.8%-22.6%]和 15.9%[95%CI 12.5%-19.9%])。所有内镜医师组的 ADR 均有增加,而不论基线 ADR 如何。
在 FIT 为基础的 CRC 筛查项目中纳入 CADe 可显著提高 ADR 和 APC。CADe 的影响似乎与内镜医师的基线 ADR 无关。